

## EVENT DETAILS

Washington Duke Inn & Golf Club  
Duke University Room  
3001 Cameron Boulevard  
Durham, NC 27705

Invite is nontransferable. No guests or spouses  
may attend.



UCB RHEUMATOLOGY INVITES YOU TO

# EXPERT PERSPECTIVES ON A NEW TREATMENT FOR PsA, nr-axSpA, AND AS

.....

**Saturday, March 15, 2025**

**6:30 PM EST**

PRESENTED BY

**Grace C Wright, MD, PhD, FACR**

Speaker is a paid consultant for UCB, Inc.

FOR MORE INFORMATION OR TO REGISTER, PLEASE CONTACT

UCB SPECIALIST: Daniel Smith & Angela Bitell

EMAIL: [daniel.smith2@ucb.com](mailto:daniel.smith2@ucb.com)

UCB SPECIALIST PHONE: 910-876-1226

EMAIL: [angela.bitell@ucb.com](mailto:angela.bitell@ucb.com)

UCB SPECIALIST PHONE: 312-256-1860

**Indications:** BIMZELX is indicated for the treatment of adult patients with active psoriatic arthritis, active non-radiographic axial spondyloarthritis with objective signs of inflammation, active ankylosing spondylitis, and moderate to severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy.

## IMPORTANT SAFETY INFORMATION

### Suicidal Ideation and Behavior

BIMZELX® (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, advise to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this activity is limited to healthcare professionals. Accordingly, attendance by guests or spouses is not appropriate, and associated expenses will not be reimbursed. Certain state and federal requirements restrict and/or require disclosure of items UCB provides to healthcare professionals, including meals and refreshments. UCB is committed to complying with all legal requirements. If you are licensed in certain jurisdictions or have institutional restrictions, UCB respectfully asks you to refrain from registering for this event. UCB will not provide alcohol at this program. Please do not forward the invitation.

Please see additional [Important Safety Information](#) on the next page and ask a UCB representative for full [Prescribing Information](#), or visit [BIMZELXhcp.com/rheum](http://BIMZELXhcp.com/rheum).

## IMPORTANT SAFETY INFORMATION (continued)

### Infections

BIMZELX may increase the risk of infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves.

### Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment.

### Liver Biochemical Abnormalities

Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase, and bilirubin at baseline, periodically during treatment with BIMZELX, and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently

discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis.

### Inflammatory Bowel Disease

Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.

### Immunizations

Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.

### MOST COMMON ADVERSE REACTIONS

Most common ( $\geq 1\%$ ) adverse reactions in plaque psoriasis include upper respiratory tract infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, Herpes Simplex infections, acne, folliculitis, other candida infections, and fatigue.

Most common ( $\geq 2\%$ ) adverse reactions in PsA, nr-axSpA, and AS include upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections. Other most common ( $\geq 2\%$ ) adverse reactions specific to each indication include: urinary tract infections (PsA); cough, fatigue, musculoskeletal pain, myalgia, tonsillitis, transaminase increase, and urinary tract infections (nr-axSpA); injection site pain, rash, and vulvovaginal mycotic infections (AS).



**Bimzelx**<sup>®</sup>  
(bimekizumab-bkzx)

Please see [Important Safety Information](#) and ask a UCB representative for full [Prescribing Information](#), or visit [BIMZELXhcp.com/rheum](https://www.bimzelxhcp.com/rheum).